News Features The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations L.A. McKeown December 24, 2020
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2020 FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease Todd Neale November 16, 2020
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Daily News Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis Caitlin E. Cox February 07, 2020
News Daily News Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication Michael O'Riordan January 17, 2020
News Daily News Diabetes Does Not Appear to Hinder FFR Insights for CAD Caitlin E. Cox January 09, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020